Tallon Kerry Patrick Purchases New Position in Codexis, Inc. (NASDAQ:CDXS)

Tallon Kerry Patrick acquired a new position in Codexis, Inc. (NASDAQ:CDXS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 403,667 shares of the biotechnology company's stock, valued at approximately $2,018,000. Codexis makes up approximately 1.9% of Tallon Kerry Patrick's investment portfolio, making the stock its 15th largest holding. Tallon Kerry Patrick owned about 0.50% of Codexis as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. abrdn plc boosted its stake in Codexis by 62.5% in the 3rd quarter. abrdn plc now owns 800,410 shares of the biotechnology company's stock worth $2,465,000 after purchasing an additional 307,762 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Codexis by 23.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company's stock worth $3,399,000 after acquiring an additional 209,207 shares during the last quarter. AQR Capital Management LLC grew its stake in Codexis by 82.4% during the second quarter. AQR Capital Management LLC now owns 237,272 shares of the biotechnology company's stock valued at $736,000 after acquiring an additional 107,205 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Codexis by 34.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 340,762 shares of the biotechnology company's stock valued at $1,056,000 after acquiring an additional 87,457 shares during the last quarter. Finally, Barclays PLC increased its holdings in Codexis by 51.1% in the 3rd quarter. Barclays PLC now owns 207,628 shares of the biotechnology company's stock valued at $640,000 after acquiring an additional 70,255 shares during the last quarter. 78.54% of the stock is currently owned by institutional investors.

Codexis Price Performance

Shares of Codexis stock traded up $0.08 during trading hours on Friday, reaching $5.00. The company's stock had a trading volume of 638,754 shares, compared to its average volume of 670,050. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. Codexis, Inc. has a one year low of $2.53 and a one year high of $6.08. The firm has a 50 day moving average price of $4.78 and a 200-day moving average price of $3.71. The stock has a market cap of $406.90 million, a P/E ratio of -5.75 and a beta of 2.13.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). The company had revenue of $12.83 million for the quarter, compared to analysts' expectations of $11.64 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. During the same quarter last year, the company earned ($0.26) earnings per share. On average, analysts predict that Codexis, Inc. will post -0.77 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and set a $11.00 price objective on shares of Codexis in a research report on Friday, November 22nd. Benchmark reaffirmed a "hold" rating on shares of Codexis in a research note on Monday, November 4th.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.